Market open
Personalis/$PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
$PSNL
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
229
Website
Personalis Metrics
BasicAdvanced
$317M
-
-$1.37
1.73
-
Price and volume
Market cap
$317M
Beta
1.73
52-week high
$7.20
52-week low
$1.14
Average daily volume
1.1M
Financial strength
Current ratio
6.522
Quick ratio
6.205
Long term debt to equity
17.238
Total debt to equity
21.852
Interest coverage (TTM)
-2,844.46%
Management effectiveness
Return on assets (TTM)
-17.23%
Return on equity (TTM)
-48.91%
Valuation
Price to revenue (TTM)
2.514
Price to book
1.51
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
-4.55
Growth
Revenue change (TTM)
15.15%
Earnings per share change (TTM)
-38.97%
3-year revenue growth (CAGR)
-0.34%
3-year earnings per share growth (CAGR)
-2.72%
What the Analysts think about Personalis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Personalis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Personalis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Personalis News
AllArticlesVideos
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
Business Wire·2 weeks ago
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 weeks ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Personalis stock?
Personalis (PSNL) has a market cap of $317M as of March 19, 2025.
What is the P/E ratio for Personalis stock?
The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of March 19, 2025.
Does Personalis stock pay dividends?
No, Personalis (PSNL) stock does not pay dividends to its shareholders as of March 19, 2025.
When is the next Personalis dividend payment date?
Personalis (PSNL) stock does not pay dividends to its shareholders.
What is the beta indicator for Personalis?
Personalis (PSNL) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.